<DOC>
	<DOCNO>NCT01426204</DOCNO>
	<brief_summary>This Phase 4 , descriptive , observational , open , prospective study patient doctor prescribes INFERGEN clinical practice . No medication provide sponsor . The planned observation time 48 week 24 week follow-up . Each investigator participate registry employ discretion standard clinical practice determine see patient clinic , manage patient 's drug regimen , best monitor patient 's response tolerance therapy .</brief_summary>
	<brief_title>Efficacy , Safety Adherence Patients Infected With Hepatitis C Virus Retreat With INFERGEN ( Interferon Alfacon1 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon alfacon-1</mesh_term>
	<criteria>1 . Willing consent data collect 2 . Considered investigator appropriate patient treatment INFERGEN retreatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Retreatment</keyword>
	<keyword>Failures</keyword>
	<keyword>Infergen</keyword>
	<keyword>Interferon Alfacon-1</keyword>
</DOC>